Gufic BioSciences Fair Value
Gufic BioSciences fair value. Gufic BioSciences (GUFICBIO) average fair value is ₹585.23 across 5 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, vs a current market price of ₹419.7 (+39.44%), fair value range ₹41.62–₹1938.47. Check GUFICBIO company valuation to track the company's total market size over time.
Fair Value Analysis Export
GUFICBIO Fair Value vs Current Price — Valuation Summary
GUFICBIO average fair value, fair value range, price gap and valuation status across 5 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number. For live price and a broader fundamental view, visit GUFICBIO screener.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
GUFICBIO Fair Value Analysis — Data Sources & Coverage
Gufic BioSciences financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. Explore GUFICBIO fundamental worth to estimate fundamental worth using multiple valuation models.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
GUFICBIO vs Healthcare Sector Peers — P/E, P/B & Market Cap
Gufic BioSciences P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Emcure Pharmaceuticals | EMCURE | 35.85 | 7.38 | ₹37,156 |
| Syngene International | SYNGENE | 68.69 | 3.13 | ₹15,000 |
| Divis Laboratories | DIVISLAB | 87.22 | 15.22 | ₹253,522 |
| Aurobindo Pharma | AUROPHARMA | 25.97 | 2.54 | ₹96,479 |
| Sat Kartar Life | SATKARTAR | 16.56 | 4.14 | ₹307 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.